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Abstract
To evaluate the use of amyloid-positron emission tomography (PET) in routine clinical practice, in a selected population with cognitive
impairment that meets appropriate use criteria (AUC).
A multicenter, observational, prospective case-series study of 211patients from 2 level-3 hospitals who fulfilled clinical AUC for
amyloid-PET scan in a naturalistic setting. Certainty degree was evaluated using a 5-point Likert scale: 0 (very low probability); 1 (low
probability); 2 (intermediate probability); 3 (high probability); and 4 (practically sure), before and after amyloid PET. The treatment plan
was considered as cognition-specific or noncognition-specific.
Amyloid-PET was positive in 118 patients (55.9%) and negative in 93 patients (44.1%). Diagnostic prescan confidence according
amyloid-PET results showed that in both, negative and positive-PET subgroup, the most frequent category was intermediate
probability (45.7% and 55.1%, respectively). After the amyloid-PET, the diagnostic confidence showed a very different distribution,
that was, in the negative-PET group the most frequent categories are very unlikely (70.7%) and unlikely (29.3%), while in the positive-
PET group were very probable (57.6%) and practically sure (39%). Only in 14/211 patients (6.6%) the result of the amyloid-PET did
not influence the diagnostic confidence, while in 194 patients (93.4%), the diagnostic confidence improved significantly after amyloid-
PET results. The therapeutic intention was modified in 93 patients (44.1%). Specific treatment for Alzheimer disease was started,
before amyloid-PET, in 80 patients (37.9%).
This naturalistic study provides evidence that the implementation of amyloid-PET is associated with a significant improvement in
diagnostic confidence and has a high impact on the therapeutic management of patients with mild cognitive impairment fulfilled
clinical AUC.
Abbreviations: AD = Alzheimer disease, AIT = amyloid imaging taskforce, AUC = appropriate use criteria, CBNU = cognitive
behavioral neurology unit, CSF-B= cerebrospinal fluid biomarkers, FBB= F-18-florbetaben, MCI=mild cognitive impairment, MRI =
magnetic resonance imaging, PET &EQUALS; positron emission tomography.
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11. Introduction
In the epidemiologic context of the progressive population aging,
the early diagnosis of Alzheimer disease (AD) is an emerging
problem of growing magnitude. The clinical approach to the
cognitive impairment and the AD, which is its most prevalent
form,[1,2] has undergone a change in recent years since the
definition of NINCD-ADRDA criteria for the clinical diagnosis of
AD in 1984.[3] The incorporation of the theory of biomarkers[4]
within the classic hypothesis of the amyloid cascade[5] has
radically modified the diagnostic approach of AD during the life
of the patients, trying to solve the clinical problem of a reliable
and early diagnosis of the disease as a continuum.[6]
Nuclear medicine has contributed to the management of
dementias and particularly AD, not only by allowing the
identification of neurodegeneration before the macroscopic
deterioration of the gray matter with positron emission
tomography (PET) with F-18-2-fluoro-2-deoxy-D-glucose
(FDG), but also by the contribution of amyloid-PET, as a
biomarker in vivo with proven analytical validity.[7]
Since its introduction in a research context C-11-PiB[8] has
demonstrated to be a useful tool to obtain “in vivo” imaging of
the amyloid plaque, one of the hallmarks of AD. It uses, restricted
Triviño-Ibáñez et al. Medicine (2019) 98:29 Medicineto centers with onsite cyclotron has been overcome with the
availability of fluorinated compounds (as F-18-florbetaben
[FBB]), which allow a widespread clinical use.[9] Despite
progress, amyloid-PET is considered an expensive, complicated
and scarcely available procedure, without studies that support it.
In general terms, there is not enough evidence to recommend the
use in the clinic[10] and some clinical problems remain
unresolved, such as the assessment of the validity and reliability
of this diagnostic test in clinical practice.[10–14] This situation
leads to a vicious circle: its use is not recommended because there
is no evidence and there is no evidence because it is not
recommended its use.
In the past years the Alzheimer’s Association and the Society of
Nuclear Medicine andMolecular Imaging convened the Amyloid
Imaging Taskforce (AIT), aimed to identify the circumstances
under amyloid-PET would have clinical utility, setting its
recommendations in the appropriate use criteria (AUC). The
AIT considered several situations in which the added certainty of
amyloid-PET could be useful to patients and caregivers altering
the management of the disease.[11] The AUC from AIT could be
considered as restrictive,[11,15] but support the basis for the
national consensus.[16] As the authors refers in its report, its
suggestions proceed from a literature revision and the interpre-
tation of the previous knowledge in precise clinical settings, but “
. . . empirical evidence of impact on clinical outcomes is not yet
available.”[11]
In this scenario, some reports are emerging describing the
clinical utility of the amyloid-PET in a clinical naturalistic
setting.[17–19] All of them reported relevant changes in the
diagnosis, level of diagnostic uncertainty and treatment.
The objective of the present study is located exclusively in
patients fulfilling AUC for amyloid-PET and aimed to provide
information about the potential benefits of the amyloid-PET in
daily clinical management.
2. Methods
2.1. Participants
This case series included patients from 2 level-3 hospitals (A:
1.75106 inhabitants; B: 1.5106 inhabitants) who fulfilled
clinical AUC for PET-amyloid scan in agreement with
international[11] and national[16] consensuses. According re-
cruitment could be considered as ambispective (in center A in
12 cases and in center B in 6 cases, data were collected
retrospectively; in the rest of the cases the information were
collected prospectively). The population included in this
study corresponds to the total number of patients scanned
during the recruitment period between January 2014 and June
2018 without randomization, in a clinical setting: the inclusion
in this work does not interfere with the natural clinical workup.
This series does not include patients under specific clinical
trials.
Four subgroups of these patients were considered for
investigation of their beta-amyloid burden to guide clinical
management and according to AUC[11,16]:1. patients with persistent or progressive unexplained mild
cognitive impairment (MCI), defined by revised Petersen
criteria[20];2. patients fulfilling core clinical criteria for possible AD but an
atypical clinical course with no documented progression in the
patient’s records;23. those with progressive cognitive impairment or dementia and
atypically early age of onset (65 years) and4. patients fulfilling these core clinical criteria but with
cerebrovascular comorbidity, concomitant pharmacologic,
neurologic, or cognitive components (mixed etiology).
Exclusion criteria were: the presence of a metabolic disorder
(hypothyroidism, vitamin B12, or folic acid deficiencies),
psychiatric pathology (schizophrenia or depression), magnetic
resonance imaging (MRI) diagnosed cerebrovascular disease
(infarction or hemorrhage), neurologic disease affecting gnosis
(Parkinsonian syndrome, epilepsy, etc), pregnancy, glycaemia
>160mg/dL, history of substance abuse, or age <18 years. In
summary, the selected cases correspond only to patients attended
by a cognition trained neurologist, visit at a specific Cognitive
Behavioral Neurology Unit, and fulfilling consensual appropriate
criteria for amyloid-PET exploration.
All participants gave their written informed consent to
participation in the study, which complied with the principles
of the Helsinki Declaration and had formal institutional review
board approval of each respective Hospital.2.2. Clinical protocol
All participants were evaluated in a Cognitive Behavioral
Neurology Unit (CBNU) by experienced neurologists sharing
homogeneous practices in cognitive-behavioral disorders.
2.2.1. Initial assessment. Initial evaluation at CBNU included a
medical interview, informant-based history, biochemical panel,
and physical and neurological examinations using standardized
tests for neuropsychological examination of the domains of
orientation, attention, memory, executive function, language,
visual and constructive functions, and behavior. Cognition was
globally evaluated with the mini-mental estate examination[21] in
the Center A and with the FotoTest[22] in the Center B. Brain
imaging includes MRI or computed tomography.
In this first visit the potential eligibility was assessed. With the
information provided by this first evaluation the neurologist was
asked to estimate the probability of AD (vs Non-AD) as
responsible of symptomatology. Certainty degree was evaluated
using a 5-point Likert scale: 0 (very low probability; 0%–20%); 1
(low probability; 21%–40%); 2 (intermediate probability; 41%–
60%); 3 (high probability; 61%–80%); and 4 (practically sure;
81%–100%). At this visit the treatment plan was considered as
cognition-specific (eg, acetylcholinesterase inhibitors or mem-
antine hydrochloride); or non-cognition-specific (eg, anxiolytics,
hypnotics, antidepressants, antipsychotics, or anticonvulsants).
2.2.2. Specific assessment. If this initial evaluation is
inconclusive or insufficient for diagnosis, the patient is
transferred to a more specifics procedures, usually in the first
line cerebrospinal fluid by spinal puncture biomarkers (CSF-B)
and in the second line: amyloid-PET.
When lumbar puncture was not possible (rejected by the
patient; not feasible: anticoagulants, spinal problems, and brain
or spinal mass) or CSF-B offered nondiagnostic results (technical
problems; results near the reference threshold; only 1 or 2 positive
result and when result was inconsistent with clinical informa-
tion),[18] amyloid-PET was performed.
2.2.3. Third (final) diagnosis approach. When amyloid-PET
results are available, the neurologist made a re-evaluation of the
possible etiological diagnosis (and his confidence level) and about
Table 1
Amyloid-PET protocol details.
CENTER A CENTER B
Camera GE Discovery STE Siemens Biograph 16
Patient position Resting; closed eyes
Operation 3D mode
Filtering Z-Axis standard
Dose 300 MBq (8 mCi)
Acquisition start 90min post injection
Acquisition duration 20 min
Matrix size 168168
Number of slices 70
Slice thickness 4.01 mm 4.06 mm
Voxel size 16.08 (mm3) 16.48 (mm3)
Reconstruction VUE Point Iterative (5 it/35 sub) Gaussian + OS  OM (6it/21 sub)
CT Parameters Low-dose, 80 mAs, 120 kV Low-dose, 50 mAs, 120 kV
CT Matrix size 512512
CT Slice thickness 1 mm
Corrections Scatter; CT attenuation; well counter sensitivity
and activity; delayed event subtraction and normalization
Scatter; CT attenuation; slice
coincidence location with CT
CT = computed tomography, PET = positron emission tomography.
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evaluation.
In order to assess the incremental diagnostic value of amyloid-
PET the outcome variables were diagnostic confidence and
treatment plan.2.3. Amyloid-PET imaging (FBB-PET)
The imaging protocol in both centers complied with international
guidelines[9] according supplier recommendations.[23] Extended
information is available in Table 1. The FBBwas reported blinded
to the clinical information by a nuclear medicine physician as
positive (loss of grey-white matter contrast; regional cortical
tracer uptake at any of the cortical target regions: lateral
temporal, frontal, posterior cingulate-precuneus, and parietal),
negative (good grey-white matter contrast; no tracer uptake at
target regions), or inconclusive for amyloid plaque presence.[23]2.4. Statistical analysis
Mean ± standard deviation values and frequency distributions
are reported. We assessed differences in baseline characteristicsTable 2
Baseline characteristics of the overall study population and accordin
CENTER ‘A’ (n=112)
Age 61.81±6.54 [60.59–63.04]
Sex Male: 55 (49%)
Female: 57 (51%)
Patiens CBNU
∗
7200
AUC
Persistent or progressive unexplained MCI 17 (15.2%)
Clinical criteria for possible AD but atypical
clinical onset or course
22 (19.6%)
Early age onset ( 65 yr) of progressive
cognitive impairment or dementia
58 (51.8%)
Mixed etiology 15 (13.4%)
In cells: mean ± typical deviation [confidence interval].
AD=Alzheimer, AUC= appropriate use criteria (see text), CBNU = cognitive behavioral neurology unit,
∗
Estimation of total of patients attended at cognitive behavioral neurology unit (CBNU) during recruitme
3between groups using analysis of variance, Kruskal–Wallis tests,
and Pearson x2 tests when appropriate. We compare the initial
and final diagnostics confidence levels using a paired sample test
(Wilcoxon sign rank and McNemar–Bowker tests). We used x2
tests to assess differences between negative and positive amyloid
PET in the treatment plan. We set the level of significance at
P< .05. Statistical analyses were performed using SPSS version
15. (IBM, Chicago, IL).3. Results
3.1. Diagnostic evaluation and treatment before amyloid-
pet
A total of 211 patients (115 women and 96men) with a mean age
of 63.54±6.43 years were included. The baseline characteristics
of the patients are shown in Table 2. The study of routine
dementias, before the amyloid-PET, was completed in 208/211
patients (98.6%), being inconclusive in 201 cases (99.5%).
According to the AUC criteria 86 patients (40.7%) had a
progressive early-onset dementia (65 years); 55 patients
(26.1%) shown atypical presentation and/or atypical course;g to the origin center.
CENTER ‘B’ (n=99) TOTAL (n=211) P
65.48±5.73 [64.34–66.63] 63.54±6.43 [62.66–64.41] .000
Male: 41 (41%) Male: 96 (45%) .163
Female: 58 (59%) Female: 115 (55%)
6300
.000
33 (33.3%) 50 (23.7%)
33 (33.3%) 55 (26.1%)
28 (28.3%) 86 (40.7%)
5 (5.1%) 20 (9.5%)
MCI=mild cognitive impairment.
nt period (January/2014–June/2018).
Figure 1. Diagnostic confidence before and after amyloid-PET. PET = positron emission tomography.
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MCI and in 20 patients (9.5%) a mixed etiology was considered.
After this first diagnostic evaluation, the most frequent degree
of diagnostic confidence of AD was intermediate probability
(category 2) in 108 patients (51.2%); followed by low
probability (category 1) in 65 patients (30.8%) and high
probability (category 3) in 30 patients (14.2%); in only 4
patients (1.9%) the diagnosis was practically sure (category 4) or
very low probability (category 0).
Specific treatment for AD was started, before amyloid-PET, in
80 patients (37.9%).
Amyloid-PET was positive in 118 patients (55.9%) and
negative in 93 patients (44.1%).Figure 2. Diagnostic pre-scan confidence according amyloid-PET results.
PET = positron emission tomography.3.2. Diagnostic confidence before and after amyloid pet
After amyloid-PET, the diagnostic confidence showed that the
most frequent category was high probability (category 3) in 68
patients (32.2%); followed by the category very low probability
(category 0) in 65 patients (30.8%); practically sure (category 4)
in 46 patients (21.8%); low probability (category 1) in 28
patients (13.3%); and only 4 patients (1.9%) in intermediate
probability (category 2). Consequently, there was a significant
increase in categories of greater diagnostic confidence, what is
28.9% in very low probability (category 0), 18% in high
probability (category 3) and 19.9% in practically sure (category
4) (P= .05, Wilcoxon test) (Fig. 1).
Analysis of the diagnostic prescan confidence according to
amyloid-PET results showed that in both, negative and positive-
PET subgroup, the most frequent category was intermediate
probability (45.7% and 55.1%, respectively) (Fig. 2). After the
amyloid-PET, the diagnostic post-scan confidence showed a very
different distribution, that was, in the negative-PET group the
most frequent categories are very low probability (70.7%) and
low probability (29.3%); while in the positive-PET group were
high probability (57.6%) and practically sure (39%) (Fig. 3).
Figure 4 shows the change in diagnostic confidence before and
after amyloid-PET. Only in 14/211 patients (6.6%) the result of
the amyloid-PET did not influence the diagnostic confidence,4while in most of the sample, 194 patients (93.4%), the diagnostic
confidence improved significantly after amyloid-PET results.
We grouped the categories of greater diagnostic confidence
(very low probability and practically sure) and those of less
confidence (low, intermediate, and high probability). We found
that the diagnostic confidence was not modified for the all cases
(8 patients) with a greater prescan diagnostic confidence;
however, in 50.7% of cases with less diagnostic confidence
prescan, amyloid-PET results conditioned an increase in the
degree of confidence diagnostic (P< .001, McNemar test).3.3. Changes in management
Before amyloid-PET, 80 patients (37.9%) had specific treatment
for AD and 131 patients (62.1%) had not initiated treatment.
Figure 3. Diagnostic confidence in positive and negative amyloid-PET. PET = positron emission tomography.
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specific AD treatment, while 92 patients (43.6%) had no
treatment. That is, 27/80 (33.8%) patients with specific treatment
before amyloid-PET stopped receiving it after amyloid-PET
study, while in 66/131 (50.4%) patients who did not receive
specific treatment before amyloid-PET, started a treatment based
on the results of amyloid-PET. Therefore, the therapeutic
intention was modified in 93 patients (44.1%). Of these, 66
patients (71%) had a positive amyloid-PET study, while theFigure 4. Change in dia
5remaining 27 (29%) had a negative amyloid-PET. In the rest (118
cases; 55.9%) the treatment was not modified, 52/118 (44.1%)
with positive amyloid-PET and 66/118 (55.9%) with negative
amyloid-PET. A positive result in the amyloid-PET conditioned
changes in management in 66/118 patients (55.9%), whereas a
negative result in 27/93 (29%) patients (P< .001, x2 test).
Treatment in the intermediate probability subgroup of the
diagnostic confidence prescan was modified in 56/108 patients
(51.9%); of these, 42 patients (75%) had a positive amyloid-PET,gnostic confidence.
Triviño-Ibáñez et al. Medicine (2019) 98:29 Medicinewhile in the remaining 14 patients (25%) was negative. In 52/108
patients (48.1%) the management was not modified, 23 patients
(44.2%) with positive amyloid-PET and 29 patients (55.8%)
negative amyloid-PET.4. Discussion
In this naturalistic study, we have attempted to estimate the
impact of amyloid-PET on the diagnostic certainty and
therapeutic approach of AD, added to the routine diagnostic
procedures, in a subgroup of patients in which AUC recommend
the investigation of their beta-amyloid burden to assess clinical
management.[11,16] The population from which patients were
recruited is representative of the population of eastern and
southern Spain, asking for specialized help in the study of
cognitive impairment, when the initial clinical evaluation is
insufficient for diagnosis.
The clinical diagnosis suffers from limitations in the actual
clinic context.[24] The use of consensual criteria improves this
setting, but, even for dementia (not only for MCI), the
misdiagnosed rate is high.[25] Final diagnosis is not possible
“in vivo” and its approach on basis follow-up of patient could
delay the correct treatment. This study arises from this scenario,
in which the neurologist cannot wait the clinical evolution, but
need to reduce the uncertainty in the diagnosis. Ancillary
procedures as CSF-B or amyloid-PET (mandatory for investiga-
tion)[4] are now available for clinical use.
Amyloid-PET is a neuroimaging modality that is been
increasingly used to assess patients with AD.[11] Several past
and present studies investigated the cumulative utility of amyloid
imaging on the routine clinical diagnostic assessment of large sets
of patients evaluated for cognitive impairment.[19,26–29] This
work uses the AUC to select amyloid-PET candidates because
there is evidence-based consensus that benefit in decrease
diagnostic uncertainty and improve treatment suitability.[18]
The AUC could help the neurologist to request an amyloid-PET in
an appropriate context, when the evaluation of the dementia
supposes a dilemma.[30] This is important because amyloid-PET
can also identify amyloid deposition in healthy subjects, who will
not necessarily develop the disease as it occurs in a large number
of normal elderly[11] or in multiple etiologies such as Lewy bodies
or cerebral amyloid angiopathy[4] increasing the false positive
rate. On the other hand, the negative predictive value of PET is
very important, especially in a disease with high (and growing)
prevalence,[17] but always bearing in mind that the rare forms of
AD[11] can generate false negatives. In addition, the application of
the AUC could help to select amyloid-PET resources rationally
justified, due to the low availability of the test or its cost, relevant
in health systems.[31]
In the present study, the diagnostic accuracy of amyloid PET
was not addressed because does not have final histopathological
results. This estimation has been reported in previous works
confirmed by final histology[32–34] or supported by clinical
follow-up.[7,35] A preliminary and indirect approach of diagnos-
tic accuracy in this series is available in a previous study.[36]
As set above, this work aims to evaluating the clinical
usefulness of amyloid-PET as a biomarker of AD, in a naturalistic
context. Our results show that amyloid images have an additional
value in routine clinical practice. Overall, the amyloid PET study
improved the diagnostic confidence in 93.4% patients. Our
results are in line with those published by Ceccaldi et al[18]
reporting an increase in diagnostic confidence in 81.5% of the6subjects after the performance of amyloid-PET. These authors
justify this proportion of change as consequence of the high level
of pre-test diagnostic uncertainty, which in turn reflects the
complexity of the population. At this respect, our population has
some peculiarities: is younger, predominantly early onset disease
(65 years) and lower proportion of atypical forms. In our
opinion, although our subpopulations are different, they
guarantee the whole spectrum of possibilities found in clinical
practice (external validity). In general terms our results are in
agreement with others works[17,35,37,38] using a different
methodology to estimate diagnostic confidence as the percentage
of increase in diagnostic confidence, reportingmodifications from
16% to 26% (the modification in 1 step in the 5-point scale used
in this work or in Ceccaldi et al,[18] implies a 20%), and in a
population not restricted to AUC.[19]
According to the modification of confidence our sample could
not be considered as homogeneous. Starting from a clinical
setting of inconclusive or insufficient diagnostic, it seems logical
to find that after this first evaluation, the categories of diagnostic
certainty with the highest proportion of patients are the
intermediate categories (specifically in our study, 50% of the
patients were classified with an intermediate probability of AD).
When the categories are grouped: higher diagnostic confidence
(very unlikely and practically sure) and those of less confidence
(unlikely, intermediate probably and very probable), we found
that the diagnostic confidence was not modified in any cases with
a high diagnostic confidence before the scan (8 patients).
However, in 50.7% of the cases with less previous diagnostic
confidence, PET results conditioned an increase in the degree of
diagnostic confidence. These results are closed with those
previously published, reporting that the change in diagnosis
and the increase in diagnostic confidence were lower in cases with
greater pre-PET diagnostic confidence,[7,35,39] therefore, it would
support the hypothesis that amyloid PET can have greater impact
in situations with significant diagnostic problems, with greater
diagnostic uncertainty after a first line protocol for the study of
AD has been completed.
Our results show significant changes in diagnostic confidence
between positive and negative amyloid-PET subgroups, probably
because they represent 2 different scenarios.
On the one hand, in the subgroup of patients with a positive
result of amyloid-PET, in respect pre-PET categories there was a
relevant migration from intermediate stages to the categories very
probable (57.6%) and practically sure (39%). PET with amyloid
also showed a clinical utility for cases with more certain diagnosis
of AD and a positive result of amyloid-PET was also useful,
increasing confidence levels. These results (similar to previously
recognized for the CSF-B)[40] support its usefulness available to
establish the diagnosis of AD in combination with clinical
parameters.
On the other hand in the PET-amyloid negative subgroup, the
categories with the highest proportion of patients were very
unlikely (70.7%) and unlikely (29.3%). These results are not
surprising and come to highlight previous evidence reporting the
high negative predictive value of amyloid images in histopatho-
logical studies,[33] and indicates that dementia experts generally
use a negative amyloid scan as a validated method to exclude a
diagnosis of AD in the majority of complex cases; this high
negative predictive value is even more valuable when the disease
prevalence increases in the general population.
In view of our results, in consonance with other works,
amyloid-PET improves diagnostic confidence[18,41] and clinical
Triviño-Ibáñez et al. Medicine (2019) 98:29 www.md-journal.commanagement.[39,41] Our results support that the use of amyloid-
PET should be implemented as a biomarker, not only in a
research framework as suggested by the AT (N) system,[42] but
also in the study of cognitive impairment in a clinical context.
Regarding changes in the management after amyloid-PET (ie,
new medication initiated, medication withdrawn), in our series
changing were reported in 44.1% of patients. These results are
in agreement with previous studies that used similar criteria,
which report changes in treatment from 37% to 68%.[38,43]
However, our results are lower than those described by Ceccaldi
et al,[18] which reported changes in management for 80.0% of
cases; but in this series only are considerate changes in
management presuming to have a substantial impact on
management (ie, a new drug started, a drug withdrawn,
additional diagnostic tests, referred to another specialist), this
percentage is reduced to 50.7% of patients, closer to that found
in our population. This discrepancy suggests variability in
clinical practice: some neurologists indicate a specific treatment
before knowing the results of amyloid-PET, while others expect
them to indicate the treatment. We believe that this fact
reproduces what really happens in the daily clinic. Other diverse
factors, such as differences in methodological definitions,
selected variables of patient management and diagnostic
uncertainty before amyloid-PET, may have contributed to the
differences in the findings.
Changes in management were more common in patients with
higher diagnostic uncertainty, (the intermediate probability
subgroup of AD pre-PET) and the treatment was modified in
more than half of the patients (51.9%). This result is not
surprisingly and is in the same direction as those previously
described by Ceccaldi et al, who report that changes in
management were more common in patients with low pre-PET
diagnostic confidence.[18]
Interestingly, changes in management were more frequent in
patients with positive amyloid-PET compared to negative. In our
study a positive result in the amyloid-PET changes therapeutic
intention in 55.9% patients, whereas a negative result in 29%.
These results are inconsistent with those previously published by
other series, in which the treatment changes were similar in
patients with positive or negative PET amyloid.[18] As set above,
these discrepancies support the variability in clinical practice
regarding the time to start specific treatment of AD respect to
amyloid-PET report.
This study is not specifically a cost-analysis and our
contribution cannot be more than speculative but could not be
indifferent to this aspect. The prognostic and preventive
implications of an early and clear diagnosis of AD have direct
repercussions in the health systems,[44] patients[6,19] and care-
givers.[27] Cannot ignore the intangible costs and the fact that an
early diagnosis allows tomake decisions that the illness must face.
New therapies are addressed to stop the progression of disease
and it is desirable to be effective in early stages of process.[45]
Evidently, the implementation of specific early therapies could be
more cost-effective than the costs generated by the delay in the
application of a treatment, when only secondary or tertiary
prevention can be done.[6]
This study has some limitations. First, in our work postmortem
verification was not available and the main outcomemeasure was
the change in diagnostic confidence, and this outcome reflects the
beliefs of clinicians. However, the proportional change observed
in diagnostic confidence is in agreement with others previous
studies[18,27,35,37] with a similar methodological approach. Could7be desirable that a long clinical follow-up of the population
provides information on the relation of amyloid-PET results
with the parameters of diagnosis certainty and treatment
optimization. Second, the cases were recruited in a clinical frame
setting, without randomization, which may have led to an
overestimation or underestimation of the effect of amyloid-PET
in diagnostic confidence, but this naturalistic study provides
evidence that the interpretation of amyloid-PET is associated
with a significant improvement in diagnostic confidence, and it
is worthy of clinical promotion and application. Third, most
patients were included in a tertiary referral center, with a high
proportion of early-onset and atypical clinical presentations.
This can hinder translation to primary and secondary-care
levels, where the populations tend to be older, more advanced or
less complex. However, in our opinion amyloid-PET should
only be performed after exhaustive standardized protocols
applied by trained staff.[11] Finally, amyloid-PET scans have
been reported only by visual analysis, grounded in the subjective
criteria of qualified specialists. Semiquantitative procedures
could be of interest in inconclusive studies (none in our series)
and provide complementary objective information. In the
project phase of this work, the investigation team decides does
not modify the standardized protocol used in daily practice
based only in visual analysis to maximize the external validity of
our results to any other center.5. Conclusions
In conclusion, this naturalistic study provides evidence that the
performance of amyloid-PET is associated with a significant
improvement in diagnostic confidence and has a high impact on
the therapeutic management of patients with MCI, fulfilling
clinical AUC, who usually present uncertain clinical features as
early-onsets, atypical, mixed and rapid progressing presenta-
tions. Consequently we strongly recommend, based on existing
evidence and our results, to implement amyloid PET in AUC in
daily clinical practice.Author contributions
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